Poxel S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PXXLF research report →
Price Chart
About the company
Poxel S. A. , a biopharmaceutical firm in the clinical stage, is dedicated to creating innovative treatments for a range of metabolic disorders, including type 2 diabetes and various liver ailments.
- CEO
- Yves Decadt
- IPO
- 2017
- Employees
- 6
- HQ
- Lyon, FR
Get TickerSpark's AI analysis on PXXLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.66M
- P/E
- -0.35
- PEG
- -0.01
- P/S
- 1.08
- P/B
- -0.11
- EV/EBITDA
- -16.94
- Div Yield
- 0.00%
- Gross Margin
- 55.12%
- Op Margin
- -55.18%
- Net Margin
- -275.84%
- ROE
- 33.88%
- ROIC
- -33.64%
Latest fiscal year · YoY change
- Revenue
- $6.63M+234.9%
- Gross Profit
- $3.69M+369093.5%
- Op Income
- $-4,339,749
- Net Income
- $-18,299,727+47.8%
- EPS
- $-0.42+53.8%
- OCF Growth
- +31.9%
- FCF Growth
- +31.9%
- 52W High
- $0.70
- 52W Low
- $0.22
- 50D MA
- $0.24
- 200D MA
- $0.25
- Beta
- 1.28
- RSI (14)
- 0
- Avg Volume
- 11
No earnings-call transcripts are available for PXXLF yet.
- Free Float
- 67.2%
- Shares Outstanding
- 62.08M
- Float Shares
- 41.69M
Our PXXLF coverage
Recent articles, reports, and earnings notes.
No research on PXXLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PXXLF report →Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships
businesswire.com · Jun 10
Poxel Reports First Quarter 2026 Revenue and Provides a Business Update
businesswire.com · May 20
Poxel: Postponement of the Publication of the 2025 Annual Financial Statements and the Annual Financial Report
businesswire.com · Apr 30
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
businesswire.com · Mar 31
Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan
businesswire.com · Mar 25
Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position
businesswire.com · Feb 16
Poxel Announces the Implementation of an Equity Line With IRIS Capital as Part of the Execution of the Recovery Plan
businesswire.com · Feb 3
POXEL SA: The Commercial Court of Lyon Approves the Recovery Plan and Brings an End to the Judicial Reorganisation Proceedings
businesswire.com · Jan 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.